Next-Generation Synbiotic in Individuals With Overweight or Obesity

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

December 20, 2024

Study Completion Date

May 20, 2025

Conditions
Overweight and Obesity
Interventions
DIETARY_SUPPLEMENT

Synbiotic Group

"WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions.~Probiotic Ingredients:~Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"

OTHER

Placebo Group

Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pendulum Therapeutics

INDUSTRY

lead

Texas Christian University

OTHER